[go: up one dir, main page]

MX2021000343A - Vesículas para la administración sin trazas de moléculas de arn guía y/o complejos de nucleasa guiado por arn/molécula de arn guía y un método de producción de las mismas. - Google Patents

Vesículas para la administración sin trazas de moléculas de arn guía y/o complejos de nucleasa guiado por arn/molécula de arn guía y un método de producción de las mismas.

Info

Publication number
MX2021000343A
MX2021000343A MX2021000343A MX2021000343A MX2021000343A MX 2021000343 A MX2021000343 A MX 2021000343A MX 2021000343 A MX2021000343 A MX 2021000343A MX 2021000343 A MX2021000343 A MX 2021000343A MX 2021000343 A MX2021000343 A MX 2021000343A
Authority
MX
Mexico
Prior art keywords
guide rna
traceless
vesicles
delivery
production method
Prior art date
Application number
MX2021000343A
Other languages
English (en)
Inventor
Anna Cereseto
Antonio Casini
Gianluca Petris
Original Assignee
Alia Therapeutics S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alia Therapeutics S R L filed Critical Alia Therapeutics S R L
Publication of MX2021000343A publication Critical patent/MX2021000343A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe vesículas que llevan ARNg y/o complejos de ribonucleoproteína nucleasa (RNP) guiados por ARN asociado a CRISPR que se administran eficazmente a las células diana a través de proteínas fusogénicas de envoltura.
MX2021000343A 2018-07-10 2019-07-08 Vesículas para la administración sin trazas de moléculas de arn guía y/o complejos de nucleasa guiado por arn/molécula de arn guía y un método de producción de las mismas. MX2021000343A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT201800007055 2018-07-10
PCT/IB2019/055805 WO2020012335A1 (en) 2018-07-10 2019-07-08 Vesicles for traceless delivery of guide rna molecules and/or guide rna molecule/rna-guided nuclease complex(es) and a production method thereof

Publications (1)

Publication Number Publication Date
MX2021000343A true MX2021000343A (es) 2021-05-28

Family

ID=63684346

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000343A MX2021000343A (es) 2018-07-10 2019-07-08 Vesículas para la administración sin trazas de moléculas de arn guía y/o complejos de nucleasa guiado por arn/molécula de arn guía y un método de producción de las mismas.

Country Status (8)

Country Link
US (1) US20210261957A1 (es)
EP (1) EP3820995A1 (es)
JP (1) JP2021524272A (es)
KR (1) KR20210044213A (es)
BR (1) BR112021000408A2 (es)
CA (1) CA3105925A1 (es)
MX (1) MX2021000343A (es)
WO (1) WO2020012335A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
WO2019051097A1 (en) 2017-09-08 2019-03-14 The Regents Of The University Of California RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
KR20240093924A (ko) 2018-09-18 2024-06-24 브이엔브이 뉴코 인크. Arc 기반 캡시드 및 이의 용도
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
AU2020242032A1 (en) 2019-03-19 2021-10-07 Massachusetts Institute Of Technology Methods and compositions for editing nucleotide sequences
US20220195455A1 (en) * 2019-04-03 2022-06-23 University Of Georgia Research Foundation, Inc. Delivery of crispr/mcas9 through extracellular vesicles for genome editing
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020219713A1 (en) 2019-04-23 2020-10-29 Case Western Reserve University Fusogenic particles and related methods for delivering therapeutic agents to cells
JP7808292B2 (ja) 2019-06-13 2026-01-29 ザ ジェネラル ホスピタル コーポレイション 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法
AU2021236683A1 (en) 2020-03-19 2022-11-17 Intellia Therapeutics, Inc. Methods and compositions for directed genome editing
US20230365989A1 (en) * 2020-03-20 2023-11-16 The Broad Institute, Inc. Compositions and methods for enhanced lentiviral production
TW202208626A (zh) * 2020-04-24 2022-03-01 美商生命編輯公司 Rna引導核酸酶及其活性片段與變體，以及使用方法
MX2023001028A (es) 2020-07-24 2023-04-24 Massachusetts Gen Hospital Particulas similares a virus potenciadas y metodos de uso de las mismas para suministro a celulas.
CN116348768A (zh) * 2020-10-09 2023-06-27 亥姆霍兹慕尼黑中心-德国健康与环境研究中心(有限公司) 确定是否存在中和病毒的抗体的方法和筛选化合物中和病毒能力的体外方法
EP4247951A2 (en) * 2020-11-19 2023-09-27 Wake Forest University Health Sciences Vectors, systems and methods for eukaryotic gene editing
WO2022152746A1 (en) 2021-01-13 2022-07-21 Alia Therapeutics Srl K526d cas9 variants and applications thereof
WO2022261150A2 (en) 2021-06-09 2022-12-15 Scribe Therapeutics Inc. Particle delivery systems
IL311218A (en) * 2021-09-08 2024-05-01 Flagship Pioneering Innovations Vi Llc PAH Modulating Compositions and Methods
AU2022375820A1 (en) 2021-11-01 2024-06-13 Tome Biosciences, Inc. Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
CN115725658B (zh) * 2021-11-12 2025-03-04 中日友好医院(中日友好临床医学研究所) 一种新型的基于水疱性口炎病毒的crispr rna递送系统及其应用
EP4453196A1 (en) 2021-12-21 2024-10-30 Alia Therapeutics Srl Type ii cas proteins and applications thereof
WO2023194359A1 (en) 2022-04-04 2023-10-12 Alia Therapeutics Srl Compositions and methods for treatment of usher syndrome type 2a
CN115261340A (zh) * 2022-05-20 2022-11-01 四川大学 一种gh-1噬菌体病毒样颗粒、制备方法及应用
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion
WO2024056880A2 (en) 2022-09-16 2024-03-21 Alia Therapeutics Srl Enqp type ii cas proteins and applications thereof
EP4619535A1 (en) 2022-11-16 2025-09-24 Alia Therapeutics Srl Type ii cas proteins and applications thereof
CN116083488A (zh) * 2023-01-03 2023-05-09 北京镁伽机器人科技有限公司 基因编辑方法、基因编辑方法得到的细胞、基因编辑系统及其应用
CN116271102A (zh) * 2023-01-09 2023-06-23 浙江大学 用于药物递送的含修饰蛋白的双层膜囊泡及其制备方法和应用
CN120882867A (zh) 2023-01-11 2025-10-31 阿利亚治疗有限公司 Ii型cas蛋白及其应用
WO2025003344A1 (en) 2023-06-28 2025-01-02 Alia Therapeutics Srl Type ii cas proteins and applications thereof
WO2025021702A1 (en) 2023-07-21 2025-01-30 Alia Therapeutics S.R.L. Cas9 orthologue nuclease and uses thereof
EP4600357A1 (en) * 2024-02-12 2025-08-13 Technische Universität München Delivery system for gene editing tools
WO2025210147A1 (en) 2024-04-04 2025-10-09 Alia Therapeutics Srl Type v cas proteins and applications thereof
WO2025224182A2 (en) 2024-04-23 2025-10-30 Basecamp Research Ltd Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
CN119662813A (zh) * 2025-02-20 2025-03-21 聚芯堂(成都)生物科技有限公司 一种CRISPR技术检测AD靶标Micro RNA的检测试剂、试剂盒及其检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US9593356B2 (en) 2013-06-11 2017-03-14 Takara Bio Usa, Inc. Protein enriched microvesicles and methods of making and using the same
WO2015191911A2 (en) 2014-06-12 2015-12-17 Clontech Laboratories, Inc. Protein enriched microvesicles and methods of making and using the same
US20150376586A1 (en) 2014-06-25 2015-12-31 Caribou Biosciences, Inc. RNA Modification to Engineer Cas9 Activity
US9816080B2 (en) * 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
CA2978314A1 (en) 2015-03-03 2016-09-09 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
CN108290933A (zh) * 2015-06-18 2018-07-17 布罗德研究所有限公司 降低脱靶效应的crispr酶突变
CN108350449B (zh) 2015-08-28 2022-05-31 通用医疗公司 工程化的CRISPR-Cas9核酸酶
WO2017068077A1 (en) * 2015-10-20 2017-04-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering

Also Published As

Publication number Publication date
EP3820995A1 (en) 2021-05-19
US20210261957A1 (en) 2021-08-26
WO2020012335A1 (en) 2020-01-16
BR112021000408A2 (pt) 2021-06-29
CA3105925A1 (en) 2020-01-16
KR20210044213A (ko) 2021-04-22
JP2021524272A (ja) 2021-09-13

Similar Documents

Publication Publication Date Title
MX2021000343A (es) Vesículas para la administración sin trazas de moléculas de arn guía y/o complejos de nucleasa guiado por arn/molécula de arn guía y un método de producción de las mismas.
NZ783532A (en) Compositions and methods for the treatment of hemoglobinopathies
CY1125154T1 (el) Ενωσεις και συνθεσεις για ενδοκυτταρικη χορηγηση θεραπευτικων παραγοντων
EP4495235A3 (en) Grna fusion molecules, gene editing systems, and methods of use thereof
CY1125087T1 (el) Ενωσεις και συνθεσεις για ενδοκυτταρικη χορηγηση παραγοντων
MX2024001210A (es) Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia
MX2019011004A (es) Compuestos y composiciones para la administracion intracelular de agentes terapeuticos.
EP4338799A3 (en) Tumor infiltrating lymphocytes and methods of therapy
EP4253551A3 (en) Novel crispr dna and rna targeting enzymes and systems
NZ742040A (en) Engineered nucleic-acid targeting nucleic acids
WO2016154127A3 (en) Compositions and methods for treating hypertriglyceridemia
WO2017218974A3 (en) Treatment of amd using aav2 variant with aflibercept
WO2019094791A3 (en) Targeted crispr delivery platforms
MX378807B (es) Inmunotoxinas de union a cd20 para inducir internalizacion celular y metodos que usan las mismas.
EP4406585A3 (en) Nucleic acid products and methods of administration thereof
EP4406544A3 (en) Cellular targeted active ingredient delivery system
WO2017156311A3 (en) Combination vectors and methods for treating cancer
MX2021004598A (es) Inhibidores selectivos de rgmc y el uso de los mismos.
WO2017115128A3 (en) Vector-free delivery of gene editing proteins and compositions to cells and tissues
WO2020028677A3 (en) Programmable designer therapeutic fusogenic secreted gectosome vesicles for macromolecule delivery and genome modification
AU2021261423A8 (en) Compositions for treating cancer with KRAS mutations and uses thereof
EP3805385A4 (en) LENTIVIRAL VECTOR AND METHOD FOR DELIVERY OF EXOGENOUS RNA BY THE LENTIVIRAL VECTOR
GB2578394A (en) Platform for generating safe cell therapeutics
WO2021222476A3 (en) High efficiency gene delivery system
WO2019147743A8 (en) Structure-guided chemical modification of guide rna and its applications